These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9602985)

  • 61. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome.
    Dunlop SP; Jenkins D; Neal KR; Naesdal J; Borgaonker M; Collins SM; Spiller RC
    Aliment Pharmacol Ther; 2003 Jul; 18(1):77-84. PubMed ID: 12848628
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.
    Mathias JR; Clench MH; Abell TL; Koch KL; Lehman G; Robinson M; Rothstein R; Snape WJ
    Dig Dis Sci; 1998 Jun; 43(6):1347-55. PubMed ID: 9635630
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.
    Prior A; Read NW
    Aliment Pharmacol Ther; 1993 Apr; 7(2):175-80. PubMed ID: 8387353
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Loperamide treatment of the irritable bowel syndrome.
    Hovdenak N
    Scand J Gastroenterol Suppl; 1987; 130():81-4. PubMed ID: 3306904
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction.
    Jalihal A; Kurian G
    J Gastroenterol Hepatol; 1990; 5(5):507-13. PubMed ID: 2129822
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Irritable bowel syndrome and the role of 5-HT. Proceedings of a roundtable meeting. New Orleans, Louisiana, USA. May 1998.
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():1-82. PubMed ID: 10447353
    [No Abstract]   [Full Text] [Related]  

  • 67. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'.
    Nayak AK; Karnad DR; Abraham P; Mistry FP
    Indian J Gastroenterol; 1997 Oct; 16(4):137-9. PubMed ID: 9357184
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.
    Poynard T; Regimbeau C; Benhamou Y
    Aliment Pharmacol Ther; 2001 Mar; 15(3):355-61. PubMed ID: 11207510
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome.
    Corazziari E; Bytzer P; Delvaux M; Holtmann G; Malagelada JR; Morris J; Muller-Lissner S; Spiller RC; Tack J; Whorwell PJ
    Aliment Pharmacol Ther; 2003 Sep; 18(6):569-80. PubMed ID: 12969083
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome--influence on psychiatric and gastrointestinal symptoms.
    Kilkens TO; Honig A; Rozendaal N; Van Nieuwenhoven MA; Brummer RJ
    Aliment Pharmacol Ther; 2003 Jan; 17(1):43-51. PubMed ID: 12492731
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
    Whorwell PJ
    Gut; 2001 May; 48(5):596-7. PubMed ID: 11302953
    [No Abstract]   [Full Text] [Related]  

  • 72. "Kapping" visceral pain in patients with irritable bowel syndrome: does it work?
    Pasricha PJ
    Gastroenterology; 1996 Aug; 111(2):531-3. PubMed ID: 8690223
    [No Abstract]   [Full Text] [Related]  

  • 73. Irritable bowel syndrome. Managing the patient with abdominal pain and altered bowel habits.
    Lynn RB; Friedman LS
    Med Clin North Am; 1995 Mar; 79(2):373-90. PubMed ID: 7877397
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Irritable bowel syndrome: classification and conceptualization.
    Ringel Y; Drossman DA
    J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S7-10. PubMed ID: 12184143
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome.
    Prior A; Wilson KM; Whorwell PJ
    Aliment Pharmacol Ther; 1988 Dec; 2(6):535-9. PubMed ID: 2908757
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
    Houghton LA; Rogers J; Whorwell PJ; Campbell FC; Williams NS; Goka J
    Aliment Pharmacol Ther; 1997 Jun; 11(3):561-8. PubMed ID: 9218083
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brain-gut interaction in irritable bowel syndrome.
    Harris ML; Aziz Q
    Hosp Med; 2003 May; 64(5):264-9. PubMed ID: 12789734
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride).
    Page JG; Dirnberger GM
    J Clin Gastroenterol; 1981 Jun; 3(2):153-6. PubMed ID: 7016973
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serotonergic modulators in the treatment of irritable bowel syndrome: influence on psychiatric and gastrointestinal symptoms.
    Castle MZ; Silk DB; Libby GW
    Aliment Pharmacol Ther; 2003 Jun; 17(11):1425. PubMed ID: 12786637
    [No Abstract]   [Full Text] [Related]  

  • 80. Psyllium therapy in the irritable bowel syndrome. A double-blind trial.
    Longstreth GF; Fox DD; Youkeles L; Forsythe AB; Wolochow DA
    Ann Intern Med; 1981 Jul; 95(1):53-6. PubMed ID: 7018336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.